Shanghai Jiaolian Drug Research And Development Co., Ltd

This study tests a new drug, B007, against a standard treatment (cyclosporine) for people with primary membranous nephropathy, a kidney disease that causes protein leakage. About 216 adults with confirmed disease and adequate kidney function will join. The goal is to see if B007 …

This early-stage study tests a new drug given as a shot under the skin for people with a kidney condition called primary membranous nephropathy. The goal is to see if it is safe and how well it works. About 52 adults aged 18 to 75 will take part.

This study tests whether adding the experimental drug B013 to standard chemotherapy (paclitaxel) can help people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based treatments. About 90 participants will receive either the comb…

This study tests a new drug, B007, in 104 people with generalized myasthenia gravis, a condition causing muscle weakness. Participants will receive either B007 or a placebo, and researchers will measure improvements in daily activities over time. The goal is to see if B007 can be…

This study tests a new drug, B007, in 132 people with pemphigus, a serious blistering skin disease. The goal is to see if B007 can help patients achieve complete remission with minimal treatment and reduce relapses. Participants must be newly diagnosed or experiencing a flare-up,…

This study tests an injection called B001 in 132 people with a rare nerve disease called NMOSD. The goal is to see if it can prevent sudden attacks that cause vision loss, weakness, or paralysis. Participants must have had at least one attack in the past year and will be followed…